Tiffany Wu, Douglas A. Simonetto, John D. Halamka, Vijay H. Shah – 12 January 2022 – The rise in innovative digital health technologies has led a paradigm shift in health care toward personalized, patient‐centric medicine that is reaching beyond traditional brick‐and‐mortar facilities into patients’ homes and everyday lives. Digital solutions can monitor and detect early changes in physiological data, predict disease progression and health‐related outcomes based on individual risk factors, and manage disease intervention with a range of accessible telemedicine and mobile health options.

Guillaume Rossignol, Xavier Muller, Kayvan Mohkam, Remi Dubois, Jean‐Yves Mabrut – 12 January 2022

Einat Cinnamon, Eli Pikarsky – 12 January 2022

Binu V. John, Yangyang Deng, Kaley B. Schwartz, Tamar H. Taddei, David E. Kaplan, Paul Martin, Hann‐Hsiang Chao, Bassam Dahman – 11 January 2022

Vinay Sundaram, Sarvanand Patel, Kirti Shetty, Christina C. Lindenmeyer, Robert S. Rahimi, Gianina Flocco, Atef Al‐Attar, Constantine J. Karvellas, Suryanarayana Challa, Harapriya Maddur, Janice H. Jou, Michael Kriss, Lance L. Stein, Alex H. Xiao, Ross H. Vyhmeister, Ellen W. Green, Braidie Campbell, William Cranford, Nadim Mahmud, Brett E.

Pierluigi Ramadori, Shing Kam, Mathias Heikenwalder – 11 January 2022 – In association with the pandemic spreading of obesity and metabolic syndrome, the prevalence of NAFLD‐related HCC is increasing almost exponentially. In recent years, many of the underlining multifactorial causes of NAFLD have been identified, and the cellular mechanisms sustaining disease development have been dissected up to the single‐cell level.

The goal of this webinar is to review mechanisms of HBV DNA integration in the context of potential clinical relevance including HCC, clinical monitoring, treatment and emerging therapeutics towards a functional cure. Some questions to be explored re: HBV DNA integration in this webinar: What is it? How/when does it happen? What is its potential impact in liver disease pathogenesis and clinical outcome (e.g. HCC)? What are potential impact of HBV DNA integration on timing of treatment initiation, clinical monitoring and novel therapeutic development?Stefan F.

Le Yang, Wenhui Yue, Hang Zhang, Zhi Zhang, Renmin Xue, Chengbin Dong, Fuquan Liu, Na Chang, Lin Yang, Liying Li – 10 January 2022 – Angipoietin‐1 (Angpt1) and von Willebrand factor (VWF) are two important angiogenic molecules that can drive pathologic angiogenesis and progression of liver fibrosis in our previous study. MicroRNAs (miRs) participate in a variety of physiological and pathological processes, including angiogenesis. However, the critical miRs targeting Angpt1 or VWF and potential molecular mechanism underlying liver fibrosis–associated angiogenesis is not clear yet.

10 January 2022

Paul H. Hayashi, M. Isabel Lucena, Robert J. Fontana, Einar S. Bjornsson, Guruprasad P. Aithal, Huiman Barnhart, Andres Gonzalez‐Jimenez, Qinghong Yang, Jiezhun Gu, Raul J. Andrade, Jay H. Hoofnagle – 10 January 2022